癌症相关静脉血栓栓塞的临床预测模型:两个独立前瞻性队列的开发与验证研究
研究利用前瞻性维也纳癌症与血栓研究(CATS)队列(n=1423)筛选预后变量,构建癌症相关静脉血栓栓塞临床预测模型,并在前瞻性国际癌症患者静脉血栓栓塞高危识别队列研究(MICA)队列(n=832)中进行外部验证。最终模型仅纳入肿瘤部位风险类别与连续D-二聚体浓度两个变量,在两个队列中区分度与校准度均良好。作者认为该模型可帮助医生筛选可能从血栓预防中获益的患者。
要点
- 最终模型仅含肿瘤部位风险类别和连续D-二聚体浓度两个变量。
- CATS队列交叉验证c指数0.66(95%CI 0.63-0.67),MICA队列0.68(0.62-0.74)。
- 模型在两个队列中校准良好,作者认为可辅助筛选血栓预防获益患者。
核心结论
- 外部验证的临床预测模型仅纳入一个临床因素(肿瘤部位类别)和一个生物标志物(D-二聚体),可预测门诊实体瘤患者的静脉血栓栓塞风险。
- 该简单模型较既往癌症相关静脉血栓栓塞预测模型有相当改进,可帮助医生筛选可能从血栓预防中获益的患者。
研究设计与样本
- 使用前瞻性维也纳癌症与血栓研究(CATS)队列(n=1423)数据筛选预后变量并构建模型。
- 在前瞻性国际癌症患者静脉血栓栓塞高危识别队列研究(MICA)队列(n=832)中进行外部验证。
主要发现
- 最终模型纳入肿瘤部位风险类别(低或中 vs 高 vs 极高)和连续D-二聚体浓度两个变量。
- 多变量子分布风险比:高或极高 vs 低或中为1.96(95%CI 1.41-2.72;p=0.0001)。
- D-二聚体浓度每翻倍的多变量子分布风险比为1.32(95%CI 1.12-1.56;p=0.001)。
- 最终模型交叉验证c指数在CATS为0.66(95%CI 0.63-0.67),在MICA为0.68(95%CI 0.62-0.74)。
- 临床预测模型在两个队列中校准均充分。
关键数值与推荐
- 肿瘤部位风险类别:高或极高 vs 低或中,子分布风险比1.96(95%CI 1.41-2.72;p=0.0001)。
- D-二聚体浓度每翻倍,子分布风险比1.32(95%CI 1.12-1.56;p=0.001)。
- 模型交叉验证c指数:CATS 0.66(95%CI 0.63-0.67),MICA 0.68(95%CI 0.62-0.74)。
临床怎么用
- 作者认为该模型可帮助医生筛选可能从血栓预防中获益的门诊实体瘤患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Venous thromboembolism is a common complication of cancer, but the risk of developing venous thromboembolism varies greatly among individuals and depends on numerous factors, including type of cancer. We aimed to develop and externally validate a clinical prediction model for cancer-associated venous thromboembolism. METHODS: We used data from the prospective Vienna Cancer and Thrombosis Study (CATS) cohort (n=1423) to select prognostic variables for inclusion in the model. We then validated the model in the prospective Multinational Cohort Study to Identify Cancer Patients at High Risk of Venous Thromboembolism (MICA) cohort (n=832). We calculated c-indices to show how the predicted incidence of objectively confirmed venous thromboembolism at 6 months compared with the cumulative 6-month incidences observed in both cohorts. FINDINGS: Two variables were selected for inclusion in the final clinical prediction model: tumour-site risk category (low or intermediate vs high vs very high) and continuous D-dimer concentrations. The multivariable subdistribution hazard ratios were 1·96 (95% CI 1·41-2·72; p=0·0001) for high or very high versus low or intermediate and 1·32 (95% CI 1·12-1·56; p=0·001) per doubling of D-dimer concentration. The cross-validated c-indices of the final model were 0·66 (95% CI 0·63-0·67) in CATS and 0·68 (0·62-0·74) in MICA. The clinical prediction model was adequately calibrated in both cohorts. INTERPRETATION: An externally validated clinical prediction model incorporating only one clinical factor (tumour-site category) and one biomarker (D-dimer) predicted the risk of venous thromboembolism in ambulatory patients with solid cancers. This simple model is a considerable improvement on previous models for predicting cancer-associated venous thromboembolism, and could aid physicians in selection of patients who will likely benefit from thromboprophylaxis. FUNDING: Austrian Science Fund, Austrian National Bank Memorial Fund, and participating hospitals.
引用
- Pabinger I, van Es N, Heinze G, et al. A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol. 2018. PMID: 29885940. doi:10.1016/S2352-3026(18)30063-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。